Literature DB >> 19470802

MicroRNA: a new entrance to the broad paradigm of systems molecular medicine.

Mingyu Liang1.   

Abstract

Systems molecular medicine is the science of combining systems biology with molecular analysis and intervention to address clinically relevant questions. MicroRNAs (miRNAs) appear particularly suitable to serve as hubs of regulatory networks underlying complex diseases. Clear experimental evidence for coordinated regulation of a large number of genes by miRNAs, however, is still rare. It leaves open several fundamental questions that are important for determining the value of miRNA in complex regulatory networks and in systems molecular medicine. Physiological genomics is a powerful approach for addressing these open questions.

Mesh:

Substances:

Year:  2009        PMID: 19470802      PMCID: PMC2712222          DOI: 10.1152/physiolgenomics.00080.2009

Source DB:  PubMed          Journal:  Physiol Genomics        ISSN: 1094-8341            Impact factor:   3.107


  21 in total

1.  Discovery and profiling of bovine microRNAs from immune-related and embryonic tissues.

Authors:  Luiz L Coutinho; Lakshmi K Matukumalli; Tad S Sonstegard; Curtis P Van Tassell; Louis C Gasbarre; Anthony V Capuco; Timothy P L Smith
Journal:  Physiol Genomics       Date:  2006-11-14       Impact factor: 3.107

2.  Integrative pathway knowledge bases as a tool for systems molecular medicine.

Authors:  Mingyu Liang
Journal:  Physiol Genomics       Date:  2007-05-08       Impact factor: 3.107

Review 3.  Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?

Authors:  Witold Filipowicz; Suvendra N Bhattacharyya; Nahum Sonenberg
Journal:  Nat Rev Genet       Date:  2008-02       Impact factor: 53.242

Review 4.  Getting to the root of miRNA-mediated gene silencing.

Authors:  Ana Eulalio; Eric Huntzinger; Elisa Izaurralde
Journal:  Cell       Date:  2008-01-11       Impact factor: 41.582

5.  MicroRNA-target pairs in the rat kidney identified by microRNA microarray, proteomic, and bioinformatic analysis.

Authors:  Zhongmin Tian; Andrew S Greene; Jennifer L Pietrusz; Isaac R Matus; Mingyu Liang
Journal:  Genome Res       Date:  2008-01-29       Impact factor: 9.043

Review 6.  MicroRNA: a new frontier in kidney and blood pressure research.

Authors:  Mingyu Liang; Yong Liu; Domagoj Mladinov; Allen W Cowley; Hariprasad Trivedi; Yi Fang; Xialian Xu; Xiaoqiang Ding; Zhongmin Tian
Journal:  Am J Physiol Renal Physiol       Date:  2009-04-01

7.  Multilevel regulation of gene expression by microRNAs.

Authors:  Eugene V Makeyev; Tom Maniatis
Journal:  Science       Date:  2008-03-28       Impact factor: 47.728

8.  microRNAs put their signatures on the heart.

Authors:  Eva van Rooij; Eric N Olson
Journal:  Physiol Genomics       Date:  2007-09-11       Impact factor: 3.107

9.  Altered microRNA expression in human heart disease.

Authors:  Sadakatsu Ikeda; Sek Won Kong; Jun Lu; Egbert Bisping; Hao Zhang; Paul D Allen; Todd R Golub; Burkert Pieske; William T Pu
Journal:  Physiol Genomics       Date:  2007-08-21       Impact factor: 3.107

10.  MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins.

Authors:  Srikumar Sengupta; Johan A den Boon; I-How Chen; Michael A Newton; Stephen A Stanhope; Yu-Juen Cheng; Chien-Jen Chen; Allan Hildesheim; Bill Sugden; Paul Ahlquist
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-04       Impact factor: 11.205

View more
  26 in total

Review 1.  The miR-29 family: genomics, cell biology, and relevance to renal and cardiovascular injury.

Authors:  Alison J Kriegel; Yong Liu; Yi Fang; Xiaoqiang Ding; Mingyu Liang
Journal:  Physiol Genomics       Date:  2012-01-03       Impact factor: 3.107

Review 2.  Vascular smooth muscle phenotypic diversity and function.

Authors:  Steven A Fisher
Journal:  Physiol Genomics       Date:  2010-08-24       Impact factor: 3.107

Review 3.  Translational study of microRNAs and its application in kidney disease and hypertension research.

Authors:  Alison J Kriegel; Domagoj Mladinov; Mingyu Liang
Journal:  Clin Sci (Lond)       Date:  2012-05-01       Impact factor: 6.124

Review 4.  Endothelial epigenetics in biomechanical stress: disturbed flow-mediated epigenomic plasticity in vivo and in vitro.

Authors:  Yi-Zhou Jiang; Elisabetta Manduchi; Juan M Jiménez; Peter F Davies
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-04-02       Impact factor: 8.311

Review 5.  Epigenetic Mechanisms and Hypertension.

Authors:  Mingyu Liang
Journal:  Hypertension       Date:  2018-12       Impact factor: 10.190

6.  MiR-222 overexpression promotes proliferation of human hepatocellular carcinoma HepG2 cells by downregulating p27.

Authors:  Yue-Feng Yang; Fei Wang; Jun-Jie Xiao; Yang Song; Ying-Ying Zhao; Yan Cao; Yi-Hua Bei; Chang-Qing Yang
Journal:  Int J Clin Exp Med       Date:  2014-04-15

7.  An Endocrine Genetic Signal Between Blood Cells and Vascular Smooth Muscle Cells: Role of MicroRNA-223 in Smooth Muscle Function and Atherogenesis.

Authors:  Zhen Shan; Shanshan Qin; Wen Li; Weibin Wu; Jian Yang; Maoping Chu; Xiaokun Li; Yuqing Huo; Gary L Schaer; Shenming Wang; Chunxiang Zhang
Journal:  J Am Coll Cardiol       Date:  2015-06-16       Impact factor: 24.094

8.  MicroRNA-10a regulation of proinflammatory phenotype in athero-susceptible endothelium in vivo and in vitro.

Authors:  Yun Fang; Congzhu Shi; Elisabetta Manduchi; Mete Civelek; Peter F Davies
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-12       Impact factor: 11.205

Review 9.  MiR-146a/b: a family with shared seeds and different roots.

Authors:  Mark R Paterson; Alison J Kriegel
Journal:  Physiol Genomics       Date:  2017-02-17       Impact factor: 3.107

10.  Downregulation of microRNA-382 is associated with poor outcome of esophageal squamous cell carcinoma.

Authors:  Bo Qi; Jian-Guo Lu; Wen-Jian Yao; Ting-Min Chang; Xiu-Guang Qin; Ying-Hua Ji; Tian-Yun Wang; Shang-Guo Liu; Han-Chen Li; Yu-Zhen Liu; Bao-Sheng Zhao
Journal:  World J Gastroenterol       Date:  2015-06-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.